A preliminary phone screening will be conducted to assess your general health and determine if you meet the necessary prequalifications for participation in our clinical trial. If you qualify based on this initial assessment, you will receive an invitation to undergo a more thorough evaluation by one of our physicians. This step is essential to ensure the safety and appropriateness of your participation in our clinical research studies.

Participants will provide consent to participate in the study by signing an Informed Consent Form (ICF). Following the signing of the ICF, participants will complete initial screening assessments to evaluate their eligibility for the study. These assessments are designed to determine if the participant meets the specific criteria required for safe and effective involvement in the clinical trial.

If all eligibility criteria are met, participants will be enrolled in the study and will begin receiving a randomized treatment regimen. Regular follow-up appointments will be scheduled to monitor the participants' progress, assess treatment response, and ensure compliance with study protocols. Participants will be provided with detailed information about what to expect during these appointments, including assessments and any additional evaluations that may be required. Ongoing communication will be maintained to address any questions or concerns throughout the study duration.

After randomization, participants enter the critical treatment phase to evaluate the efficacy and safety of the intervention. Participants will receive their assigned treatment, including new medications or devices, under clinical supervision to ensure correct application and monitor reactions. Regular visits follow initial treatment to monitor responses, collect side effect data, and ensure protocol adherence. Healthcare professionals perform assessments at follow-ups, including physical exams, lab tests, questionnaires, and imaging to track progress and treatment effectiveness. Participants are closely monitored for adverse effects throughout the trial.

At the conclusion of the clinical trial, participants will undergo a structured end-of-treatment assessment to evaluate their overall health and response to the investigational intervention. This phase is critical for understanding the efficacy and safety of the treatment, as well as for gathering valuable data for future analyses.

Following the end of treatment, participants will be scheduled for follow-up assessments at specified intervals. These assessments may include clinical evaluations, questionnaires, safety monitoring, and laboratory tests. Participants will be contacted at follow-up points and encouraged to report any new symptoms or changes in health. Data collected during follow-up will be essential in determining the long-term safety and effectiveness of the intervention, ultimately contributing to the broader field of clinical research and patient care.